One sentence summary: A new approach to predict combination therapies based on modeling signaling networks using phosphoproteomics from Multiple Sclerosis patients identifies deregulated pathways and new drug combinations.
Abstract
Signal transduction deregulation is a hallmark of many complex diseases, including Multiple Sclerosis (MS). Here, we performed ex vivo multiplexed phosphoproteomic assays upon perturbations with multiple drugs and ligands in primary immune cells from 169 MS patients and matched healthy controls. Patients were either untreated or treated with fingolimod, natalizumab, interferon-β, glatiramer acetate or the experimental therapy epigallocatechin gallate (EGCG). We generated for each donor a dynamic logic model by fitting a bespoke literature-derived network of MS-related pathways to the perturbation data. Analysis of the models uncovered features of healthy-, disease-and drug-specific signaling networks. We developed an approach based on network topology to identify deregulated interactions whose activity could be reverted to a "healthy-like" status by combination therapy. We predicted several combinations with approved MS drugs. Specifically, TAK1 kinase, involved in TGF-β, Toll-like receptor, B-cell receptor and response to inflammation pathways were found to be highly deregulated and co-druggable with all MS drugs studied. One of these predicted combinations, fingolimod with a TAK1 inhibitor, was validated in an animal model of MS. Our approach based on donor-specific signaling networks enables prediction of targets for combination therapy for MS and other complex diseases.
Introduction
The signal transduction machinery is frequently affected by perturbations induced by complex diseases. Hence, treatment of diseases such as cancer, cardiovascular, immunological or brain diseases is nowadays largely attempted by modulating different molecular cascades involved in the disease to stop its progression. As such, kinases involved in signaling processes have evolved as primary targets for many diseases (1) .
Further, there has been modest progress with treatments based on single drugs.
Combining several drugs targeting different pathways promises more effective modulation of the pathogenic process (2, 3) . However, development of combination therapies is hampered by the often incomplete understanding on how their effect propagates through complex signaling networks, with crosstalk between the pathways influenced by each therapy (4, 5) . As an additional level of complication, disease heterogeneity hinders predicting how a specific combination therapy could be translated into the clinic. Last, the combinatorial nature of such studies in terms of number of targets, drugs, doses, and therapeutic regimens implies a large number of experiments and associated costs, preventing a complete analysis for all alternatives. As a result, the full potential of combination therapies has not been fully developed yet.
Systems biology, and more specifically modeling of signaling pathways applied to drug discovery, may provide a new path to approach this question (2, 6) . Mechanistic understanding at the network level offers integrated insights about the cellular responses to environmental changes (7) and drug effects, yielding a significant understanding of the signaling cascades derived from decades of research in this field (8) (9) (10) . Mathematical modeling of signaling networks has been used to unravel signaling mechanisms, discover drug targets and disease mediators such as cell surface receptors or intracellular molecules by training those models to experimental in vitro measurements of key pathway components using inhibitors and activators (4, 11, 12) . Modeling-based studies may be the key to characterize the effect of drug combinations at the molecular level and allow us to predict both efficacy and reduction of off-target effects (5, 11, 13) .
Multiple Sclerosis (MS) is an autoimmune disease, in which the immune system is chronically activated and damages the central nervous system (CNS) (14) . The involvement of immune system deregulation in MS is shown by altered phenotype and activity of blood lymphocytes and monocytes (14) , as well as by association with genetic polymorphisms of immune genes (15) . At present, there are fifteen FDA-approved immunomodulatory drugs, and many others are in late stage clinical development. Most of these control the inflammatory activity in patients with MS to a certain degree, though with known unwanted effects at the signaling level. Furthermore, many unmet medical needs remain in the attempt of achieving control of the disease including more effective therapies, a good safety profile and neuroprotective or regenerative treatments. Drug combinations are considered as a promising strategy to overcome some of these limitations, and in cancer combination therapies they are well established (16) .
However, predicting which patients would benefit the most from a certain combination therapy remains as an unresolved challenge (17) (18) (19) (20) .
In this study we present a systems medicine approach aimed to (i) characterize the signaling pathways in primary immune cells obtained from blood of MS patients and healthy controls, and (ii) predict new combination therapies based on the differences in signaling networks between treated MS patients and controls ( Figure 1 ). To this end, we assembled a literature-and database-based Prior Knowledge signaling Network (PKN) (21) , which includes the pathways involved in immune and MS signaling, as well as their crosstalk and known therapeutic targets. Based on their ability to model large networks with a low number of parameters, logic models have been used to unravel the network topology driving disease and response to therapy (22) (23) (24) (25) . Here, we established a Boolean logic model from the signaling network and trained it with measurements of kinase de/phosphorylation as a proxy of signal propagation upon perturbation with ligands and drugs in Peripheral Blood Mononuclear Cells (PBMCs) from MS patients and healthy controls. We determined disease-and therapy-specific logic models that characterize the signaling networks for approved treatments (interferon-beta (IFNβ), glatiramer acetate (GA), natalizumab (NTZ), fingolimod (FTY) and the experimental drug epigallocatechin gallate (EGCG)). We hypothesized that the signaling interactions that the drugs failed to revert in the ex vivo assays to a healthy-like activity level may be candidates to be targeted by a second drug and hence lead to a personalized combination therapy. To identify those interactions, we developed a score of co-druggability of signaling interactions according to quantitative differences in network topology among healthy controls and untreated and treated MS patients ( Figure 1 and Table 1 ).
Using this network-based approach, we predicted several combination therapies, in particular of TAK1 with all five studied MS drugs. We validated a highly-scoring combination therapy in the animal model of MS experimental autoimmune encephalomyelitis (EAE). The modeling approach shown here can be used for designing combination therapies for other complex diseases as well as for developing personalized therapies. interactions to find co-druggable network interactions. The score is calculated to identify interactions that differ from healthy-like signaling activity in spite of drug treatment (see methods). C) Topological prediction of drug combination. A topology-based graph search allows identifying secondary treatments that could target and revert signaling of co-druggable interactions to a healthy-like activity state. Table 1 . Illustration of co-druggability score for extreme combinations of Healthy-MS-Treated signaling activity. Implications for each score using as an illustration extreme signaling activities. Based on the signaling activity of each interaction as assessed by modeling, the difference between healthy, untreated MS and treated MS (columns 1-3 for a given interaction) can be calculated, yielding a score (column 4). The implications for each score are shown in columns 5 and 6 . Interactions with a negative co-druggability score indicated a treatment effect that produced signaling activity different to that found in healthy patients and were selected as co-druggable. A co-druggability score of 0 indicated that there was no effect due to drug treatment. From those cases, the interactions, in which signaling activity was different between healthy donors and treated patients were also selected as co-druggable, i.e. those where the drug alone failed to revert signaling to a healthy state. Hence, co-druggable interactions were defined as those where treatment with the drug alone yielded signaling activity different to that of the healthy-like state.
Results

Multiplexed phosphoproteomic analyses in PBMCs from MS patients and controls
To characterize the signaling networks involved in MS, we created a Prior Knowledge Network (PKN) of biochemical interactions (kinase phosphorylation) reported to be involved in immune signaling associated with MS based on omics and functional studies, as well as those pathway interactions targeted by MS drugs (17) . Our network includes pathways such as interferon response, B-and T-cell receptor signaling, cellular survival and apoptosis, lipid signaling, innate immunity and multi-drug response (MDR) genes ( Supplementary Figure S1 ) . To achieve this, we searched in state-of-the-art databases for interactions that were reported in highly specific assays and prioritized experiments with human and PBMC cells ( Supplementary Table S1 and S2 ). Further, targets of MS drugs were included into the network via their crosstalk with immune pathways. The PKN featured 167 signaling components ( Supplementary Table S2 ) and 294 interactions ( Supplementary Table S1 ).
Subsequently, we developed a multiplex xMAP phosphoprotein panel tailored to logic modeling and aiming to maximize the coverage of the MS-specific network. The panel, which combined previously and newly developed assays, was then optimized to maximize accuracy, reproducibility as well as network coverage (see Supplementary   Table S3 and Supplementary Methods S1 ) (26) . After optimization, we selected a set of 17 phosphoproteins with adequate signal to noise ratio that were used for the in vitro assays: AKT1, CREB1, FAK1, GSK3A, HSPB1, IKBA, JUN, MK12, MK03, MP2K1, PTN11, STAT1, STAT3, STAT5, STAT6, TF65, WNK1 ( Supplementary Table S4 ).
PBMCs were cultured in presence of different sets of stimuli such as lectins, endotoxins, immunostimulants, cytokines and drugs ( Supplementary Table S5 ).
We extracted PBMCs from 195 MS patients (mean age: 43.1 + 11.3 years; disease duration: 8.7 + 7.7 years; median EDSS: 2.0 (0-6.0); subtype: 24 CIS, 129 RRMS, 6 SPMS and 36 PPMS; untreated: 98) and 60 healthy controls ( Supplementary Table   S6 ). From those 255 donors, 180 were selected and PBMCs were analyzed before stimulation and at 5 and 25 min after stimulation. This yielded a dataset consisting of three measurements for 17 phosphoproteins upon 20 stimuli, to a total of 183600 experimental measurements. For subsequent modeling, the two time points after baseline (5 and 25 min) were collapsed into a single activation signature to define whether a given phosphoprotein was activated or inhibited (see details in methods ).
Finally, we applied stringent quality control analyses of the dataset consisting of positive and negative controls, reproducibility tests as well as tests for artifacts in the distribution of the samples (see Supplementary Methods S1 ), which led to the removal of 2028 data points and 11 patients to generate the final dataset for a total of 169 subjects. After application of identifiability analysis based on the experimental coverage of our measurements (21) , the PKN (shown in Supplementary Figure S1 ) was reduced to 71 proteins and immune modulators and 168 interactions.
Logic modeling enables characterization of signaling networks in healthy donors and MS patients
Next, we sought to train the generic PKN to these phosphoproteomic measurements in a donor-specific manner to identify each donor's active pathways. To train the same Boolean logic model to the data of each of the 169 subjects, the phosphoproteomic datasets were transformed ( Figure 2A ). To enable comparison of the data to the binary output of the Boolean model, we established a stringent normalization pipeline combining (i) a non-linear transformation to normalize the measurements to continuous values between 0 and 1 while penalizing the outliers (21) with (ii) a statistical filter that removed data-points belonging to proteins that were not found to be significantly phosphorylated or dephosphorylated ( Supplementary Figure S2 ) . Figure 2B shows the log fold change of each phospho-profile with respect to the control, Figure 2C the dataset after the non-linear normalization, and Figure 2D displays the proteins found to be significantly dephosphorylated or phosphorylated. Using this normalized dataset, we aimed to identify the active specific signaling network for each donor. To this end, we fitted a general logic model derived from the PKN (21) to each donor dataset, which resulted in a compendium of 169 models. Model optimization was performed with CellNOpt, a tool that selects the logic model that best matches the data while penalizing model size (27) . To increase the robustness of each model, optimization was performed 10 times, and for each donor we selected the best solution as well as all models with a data-to-simulation mismatch within a given relative tolerance reflecting that, due to lack of identifiability and technical noise, different models are feasible (21) (see methods for details). We then built a final model for each patient, defined by the median value of each interaction across all solutions within the relative tolerance (or borders of tolerance) of the best solution ( Figure 3A ). To assess the validity and robustness of our modeling approach, we confirmed absence of bias due to treatment, center, disease subtype, medical condition, as well as technical aspects such as model size and merging strategy ( Supplementary Figure S3 ) .
To confirm that our modeling approach was able to capture the effect on signal transduction of MS drugs, intra-as well as inter-donor model similarities were calculated by the Simple Matching Coefficient (SMC) index. This means, we assessed the number of interactions in two networks that are equal in both networks over the number of all interactions, after stratification of patients by treatment subgroups ( Figure 3B ).
Modeling shows that treated MS patients (green boxes) yield more similar signaling activity than untreated MS patients (orange boxes). Treatment with FTY yielded the overall highest within-subgroup similarity and was statistically more similar in this group's patients than compared to RRMS untreated patients (untreated RRMS mean Similarity is higher within each subgroup than compared to background. C) Differentially activated pathways (see Supplementary Methods) between healthy controls (HC) and untreated MS patients (MS).
The models previously calculated for each donor were merged to reveal the common active pathways for controls (blue), untreated MS patients (orange) and both (brown). Grey: Inactive interactions from the MS, immune-and treatment-related network (Supplementary Figure S1 ).
These findings indicated that our method was able to identify previously described 
Quantitative differences found in signaling pathways under therapy
We then quantified differences in signaling between patients treated with MS-specific therapies, using the same procedure as for healthy donors versus untreated MS 
Network topology-based prediction of targeted combination therapy
Our main goal was to use the subgroup networks found to predict novel combination therapies. To this aim, we defined as therapeutic goal to revert the signaling network of patients with MS to a healthy-like activity. We introduced a restriction to our method: the combinations we sought featured one approved MS drug which, in spite of its known efficacy in MS, yielded a signaling activity that differs from the healthy controls as identified by our topological modeling approach. Thereby, we aimed to predict which kinase interactions within the network would revert signaling activity to the healthy-like state when combined with the ongoing therapy. We hypothesized that a co-druggable interaction, i.e. those that a given MS therapy failed to revert to a healthy-like activity level, should be the model interactions with a signaling value more distant between healthy control and MS drug models than between healthy control and untreated MS models ( Figure 1 and Methods ). This yielded a list of interactions with their corresponding score quantifying co-druggability potential (Supplementary Table S7 and Supplementary Figure S4 ). To identify the co-druggable interactions, we selected those with a non-positive score as described above, and filtered for additional conditions (see Methods ), thereby identifying both the interactions whose signaling activity was different from healthy because of deregulation by the disease as well as because of off-target primary drug effect ( Figure 4A ) . The last step of our approach was to predict the stimulus that would revert to healthy-like signaling activity of those interactions identified as co-druggable. Therefore, the co-druggable interactions were mapped onto the signaling network assessed for each drug subgroup. As an example, Figure 4B shows the co-druggable interactions under FTY treatment mapped onto the FTY network. Mapping the co-druggability for each interaction allowed us to predict combination therapies based on each treatment's signaling network topology. Finally, we employed a graph search approach to identify the in vitro stimulus used in our study that activated interactions found to be co-druggable with each drug. In other words, we found the experimental readouts that could be measured and reached from an in vitro stimulus via an interaction found to be co-druggable in vivo ( Supplementary Table S8 ).
It is important to note that our approach enabled the prediction of combinations of approved MS therapies which yielded a signaling activity distant from healthy controls with drugs that stimulated or inhibited signaling. Among all predictions ( Supplementary   Table S8 ), we chose to validate the combination of FTY with a TAK1 inhibitor based on (i) the striking signaling homogeneity across FTY models (as quantified in Figure 3B ),
(ii) the finding that TAK1 modulation of HSPB1 via MK12 is largely deregulated Table S7 ).
Validation of a predicted combination therapy in the animal model of MS
To validate our approach and obtain an in vivo proof-of-concept of the efficacy of the combination therapies proposed, we sought to assess whether the combination network interactions (X axis) was assessed using the co-druggability score, and those identified as co-druggable (see Figure 1 , Table 1 and main text) are shown. For each interaction (X axis) the number of drugs (Y axis) is shown, in which it was found to be co-druggable using the co-druggability criteria; B)
FTY network co-druggability: the case of FTY network co-druggability is shown as an example (red line:
interactions predicted to be co-druggable); C) In vivo validation of the combination FTY+TAK1-inhibitor in the EAE model. The graph shows the mean and the standard error of the clinical score for each group (n=10). Animals started treatment after disease onset (clinical score >1.0) and were randomized to each treatment and rated in a blinded manner.
Discussion
In this study, we applied a modeling approach to characterize signaling activity both at the donor-specific and at the subgroup level using phosphoproteomic data from primary immune cells of MS patients and healthy donors. At the subgroup level, we identified models of the signaling network for healthy controls, untreated and drug-treated MS patients. Our approach allowed us to characterize signaling deregulation in this complex and heterogeneous disease. Further, based on the data-driven models, we developed a network-based method to predict novel combination therapies for the treatment of MS.
We hypothesized that the interactions in the subgroup models in response to single drugs that were not reverted to a healthy-like activity state can be co-drugged. Hence, we developed a co-druggability score identifying those interactions. Finally, we used that score on a newly developed strategy to predict combination therapies based on network topology. Thus, our algorithm identifies interactions within signaling networks that should be targeted for restoring the network to a healthy-like state.
As validation, we tested the combination of one approved drug for MS, FTY, with an inhibitor of TAK1, a key component in the predicted signaling networks of all five studied in vivo drugs, which was found highly deregulated in FTY. This combination largely ameliorated the course of the animal model of MS with significantly higher efficacy than each treatment alone, providing in vivo proof-of-concept for our approach.
The approach presented here allows insights into signaling deregulation in MS by comparing signaling networks in untreated MS patients with those of healthy controls. by ubiquitination, including that of EGFR itself (43, 44) . In summary, our results are supported by multiple previous studies identifying deregulation of pathways in MS (17) and shows the activation of pro-inflammatory pathways and the inhibition of pathways related with immune tolerance.
Regarding the signaling models of MS drugs, our method can identify the activation of pathways downstream of drug targets in our PKN. Further, it revealed interactions with other disease-associated pathways, which may not directly be involved in the signaling elicited by such drug. Therefore, our modeling approach can be used to provide a wider context of the effects of a given drug on the functions of the target cells. For example, the models identified the activation of JAK1-STAT1 pathway (45, 46) in IFNβ-treated patients, the activation of AKT, PLC (47, 48) in patients treated with FTY, or the activation of MAPK, NFkβ (via TAK1) (49) (50) (51) in NTZ treated patients.
Our study has several limitations. First, the analysis of signaling signatures based on phosphoproteomics of mixed immune cells can give rise to high signal variability that is confounded by the presence of multiple cell types. The analysis of signaling abnormalities from specific immune cell subtypes e.g. CD4+, CD8+, B-cells, monocytes that probably differentially contribute to the disease susceptibility or to the response to therapy may reveal new therapeutic targets. This limitation can be overcome by technologies that allow to collect information at the single-cell level such as mass cytometry in future studies (52) , although the cost is considerably higher, thus limiting number of subjects. Second, our current coverage using validated xMAP assays was restricted to less than 20 kinases, a small subset of signaling molecules and pathways that may be activated in immune cells. Robust quantitative phosphoproteomic assays covering thousands of phosphosites in hundreds of samples can be used for logic modeling (53) . This will allow us to expand significantly the scope of our models. Third, the Boolean logic approach does not describe processes biochemically and models processes as binary, hence missing subtle aspects of signal transduction (10) . An important goal of our studies was to develop a modeling approach that can guide the rational development of combination therapies. Our signaling topology-based approach has the advantage of allowing prediction of combinations between drugs currently used in patients with MS and compounds that can stimulate signaling where those drugs yield a signaling activity distant from the healthy state. Many strategies have been developed to predict drug combinations (54) . Others have used phosphorylation data upon perturbation using statistical approaches (13) , data-driven network inference (5, 11) , or a combination of mechanistic and Bayesian network modeling (55) . Due to their simplicity, logic networks can model large networks and provide a useful framework to study drug combinations (23) (24) (25) . We used this logic framework to analyze a large dataset encompassing 183600 data points derived from a newly recruited cohort of 169 donors. Our approach is a compromise between data availability, technical feasibility and computational burden that sacrifices details to be able to capture a broad portion of the signaling machinery. Fourth, in this study, we have explored only some of the currently approved drugs for MS patients. And fifth, we have averaged individual patients' networks to obtain the subgroup (drug) networks, which leads to losing individual variability, probably related to differential genetic susceptibility or immune system activation.
In summary, we have built donor-specific dynamic logic models and developed a network-based approach to (i) characterize MS and treatment deregulation of signaling and (ii) predict new targets for combination therapy. This approach can be applied to other diseases.
Materials and Methods
Subjects and clinical cohorts . We recruited 255 subjects including 195 patients with MS and 60 healthy controls, matched for age and sex with the RRMS group, in a multi-centric study in four MS centers (Hospital Clinic Barcelona -IDIBAPS (n=69), Karolinska Institute (n=64), University of Zurich (n=40) and Charité University (n=82))
( Supplementary Table S5 and Supplementary Methods S1 ).
Samples and processing . A unified standard operating procedure for PBMCs isolation, stimulation and lysis, as well as sample storing and shipping was developed along with a kit (plates) with reagents and buffers that were produced in a single facility (ProtAtOnce) and shipped to all participating centers (see Supplementary Methods S1
for details). The reagents were prepared from a single batch and plates were prepared from a single batch for each stimulus. Quality controls were carried out to ensure that the reagents remain stable for 3 months. 
Model generation. Healthy controls and MS (untreated) signaling models as well as
MS drug-specific models were assembled, using manual curation to prioritize interactions that were found in immune or human cells whenever possible. To allow inclusion of MS drugs, the drug targets were included in pathways as explained above via the references detailed in Supplementary Tables S1 and S2 . The global network featured (167 nodes and 294 interactions). The identifiable components, i.e. those that led to unique solutions using the optimization algorithm, were assessed as described in Network topology-based prediction of combination therapy. We calculated the co-druggability score as described in Figure 1 with S indicating the signaling activity status of each interaction:
were Healthy refers to the healthy subgroup model, MS relates to the untreated MS subgroup model and Treatment denotes one of the five approved drug treated MS subgroup models. Therefore, interactions with a negative co-druggability score indicated a treatment effect that produced signaling activity more different from that found in healthy donors than without treatment and were selected as co-druggable. A co-druggability score of 0 indicated that there was no effect due to drug treatment.
|S Healthy -S MS | -|S Healthy -S Treatment | ≤ 0
Thus, we used the algorithm described in Figure 1 to define the co-druggability of all interactions within each treatment group after filtering for active signaling. To ensure that interactions with positive scores close to zero were also captured by our method (interactions with a similar signaling activity between drug treatment and MS untreated),
we defined a lower quartile threshold around zero and collapsed almost zero scores into zero. Further, we required co-druggable interactions to be significantly (p<0.05) different between healthy and drug signaling by using the upper quartile as difference threshold.
Applying both filters together allowed us to identify co-druggable interactions that were Code and data availability. All code, mathematical models and data can be found on Github ( http://github.com/saezlab/combiMS ).
